SCHEMBL276994

SCHEMBL276994

CC(C(N)=O)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11940027 1.00
SCHEMBL14592819 1.00
SCHEMBL28096846 0.79
SCHEMBL27345893 0.77
SCHEMBL3351302 0.77 MAPT (0.33)
SCHEMBL15759829 0.77 CA1 (0.30)
SCHEMBL20098013 0.77 CA1 (0.30)
SCHEMBL27969796 0.75 ALDH1A1 (0.37)
SCHEMBL9823163 0.75
SCHEMBL10473952 0.73 DPP4 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011016863-A2 METHODS AND USES OF CYTOCHROME P450 INHIBITORS ANGION BIOMEDICA CORP. (US) 2011-02-10 WO claimed
US-7235258-B1 Sustained-release formulations for treating CNS-mediated disorders NPS PHARMACEUTICALS, INC. (US) 2007-06-26 US claimed
EP-1576962-A1 Composition comprising isovaleramide and ibuprofen NPS PHARMACEUTICALS, INC. (US) 2005-09-21 EP claimed
US-20040072900-A1 Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound NPS PHARMACEUTICALS 2004-04-15 US claimed
CN-1409630-A Sustainable-release formulations for treating CNS-mediated disorders NPS PHARMA INC (US) 2003-04-09 CN claimed
JP-2002538106-A 2002-11-12 JP claimed
EP-1225888-A2 SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS NPS PHARMACEUTICALS, INC. (US) 2002-07-31 EP claimed
US-6383527-B1 FOR TREATMENT OF ACUTE MUSCULAR ACHES, STRAINS, AND SPRAINS WHICH OCCUR FROM A LOCALIZED, EXTERNAL INSULT TO A PARTICULAR MUSCLE OR MUSCLE GROUP NPS PHARMACEUTICALS, INC. 2002-05-07 US claimed
EP-1176953-A2 TREATMENT OF A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND NPS PHARMACEUTICALS, INC. (US) 2002-02-06 EP claimed
WO-2001028516-A2 SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS NPS PHARMACEUTICALS, INC. (US) 2001-04-26 WO claimed
EP-1059930-A1 COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID NPS PHARMACEUTICALS, INC. (US) 2000-12-20 EP claimed
WO-2000051586-A2 TREATING A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND NPS PHARMACEUTICALS, INC. (US) 2000-09-08 WO claimed
WO-1999044623-A1 COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID NPS PHARMACEUTICALS, INC. (US) 1999-09-10 WO claimed
US-11646455-B2 Secondary battery, and battery module, battery pack, and device having same CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) 2023-05-09 US disclosed
US-20230116506-A1 Polymers and Nanoparticles for Flooding SAUDI ARABIAN OIL COMPANY (SA) 2023-04-13 US disclosed
US-20220399579-A1 SECONDARY BATTERY, AND BATTERY MODULE, BATTERY PACK, AND DEVICE HAVING SAME CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) 2022-12-15 US disclosed
EP-0414058-B1 Carboxylic acid derivatives BASF AG (DE) 1994-06-15 EP disclosed
WO-1994011334-A1 SUBSTITUTED ORTHO-ETHENYL-PHENYL ACETIC ACID DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1994-05-26 WO disclosed
US-5085685-A Herbicides BASF AKTIENGESELLSCHAFT (DE) 1992-02-04 US disclosed
EP-0414058-A2 Carboxylic acid derivatives BASF Aktiengesellschaft (DE) 1991-02-27 EP disclosed